Mouse only for pivotal GLP tox (neonatal FVB); NHP only in non-GLP studies (later 6-month juvenile NHP study in label)
“Single-dose toxicology studies were conducted to evaluate the safety of AVXS-101 following a single IV administration in healthy neonatal FVB/n mice.”
✓ VerifiedFDA pharmacology/toxicology review, p. 14Source ↗
Why that species
FVB/n strain chosen as background of SMNdelta7 disease model to compare with pharmacology data; EMA noted NHP closer to human
“The Applicant has chosen to use the FVB/n strain in the toxicology studies to be able to directly compare safety data from the SMNΔ7 studies.”
No surrogate; clinical vector (Process B GMP lots) in mice; GFP reporter AAV9 used in NHP pharmacology publications
“The subsequent GLP single dose toxicity studies, Study 20122446 and Study 8384031, using GMP test material from the initial Process B manufacturing process revealed dose-dependent, delayed cardiovascular toxicity that was associated with thrombus formation in the atrium of the heart resulting in unscheduled mortality in a significant number of animals.”